ReviewNeuro-oncology2019
Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.
Review in Neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 3 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of radiotherapy in the management of patients with diffuse low grade glioma in adults: update.Journal of neuro-oncology · 2025Guideline
- Congress of neurological surgeons systematic review and evidence-based guidelines for the role of imaging in newly diagnosed WHO grade II diffuse glioma in adults: update.Journal of neuro-oncology · 2025Pooled it
- SEOM-GEINO clinical guidelines for grade 2 gliomas (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Lower-grade gliomas surgery guided by GRPR-targeting PET/NIR dual-modality image probe: a prospective and single-arm clinical trial.Theranostics · 2024Trial
- Precision medicine meets artificial intelligence: A new prognostic model for lower-grade glioma.Molecular therapy. Oncology · 2026Article
- Integrating multi-omics analysis and machine learning to refine molecular subtypes and prognostic assessment of lower-grade glioma.Molecular therapy. Oncology · 2026Article
- The Clinical Utility of Cell-Free DNA in Brain Tumor Management: A Comprehensive Review.Journal of molecular neuroscience : MN · 2025Review
- Constructing anoikis-related signatures in glioma and identifying PLAU as a new prognostic biomarker.BMC medical genomics · 2025Article
- Cell cycle-related biomarker lineage promotes the malignant progression of recurrent IDH wild-type glioma.Discover oncology · 2025Article
- A Novel Mitochondrial-Related Gene Signature for the Prediction of Prognosis and Therapeutic Efficacy in Lower-Grade Glioma.Biochemical genetics · 2025Article
- Prognostic signature based on hypoxia and RNA methylation regulatory genes can improve the prognostic and recurrence prediction ability of low-grade glioma.Translational cancer research · 2025Article
- Identification and validation of LDHA and SLC16A1 for predicting prognosis and diagnosis in lower-grade glioma.Discover oncology · 2025Article
- Prediction of 1p/19q state in glioma by integrated deep learning method based on MRI radiomics.BMC cancer · 2025Article
- Mutational accumulation drives pathway dysregulation to predict glioma patient survival.Scientific reports · 2025Article
- Neuro-oncological superiority of supratotal resection in lower-grade gliomas.Neuro-oncology · 2025Article
- Management and survival trends for diffuse gliomas diagnosed at a single neurooncology center in China during 2000 to 2020.Scientific reports · 2025Article
- Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma.Biomedicines · 2025Article
- Research Progress on Glioma Microenvironment and Invasiveness Utilizing Advanced Multi-Parametric Quantitative MRI.Cancers · 2024Review
- The 2021 World Health Organization Central Nervous System Tumor Classification: The Spectrum of Diffuse Gliomas.Biomedicines · 2024Review
- Survival Analysis of Patients Undergoing Intraoperative Contrast-enhanced Ultrasound in the Surgical Treatment of Malignant Glioma.Current medical science · 2024Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 11 institutions in 4 countries.
Funding
Abstract
The finding that most grades II and III gliomas harbor isocitrate dehydrogenase (IDH) mutations conveying a relatively favorable and fairly similar prognosis in both tumor grades highlights that these tumors represent a fundamentally different entity from IDH wild-type gliomas exemplified in most glioblastoma. Herein we review the most recent developments in molecular neuropathology leading to reclassification of these tumors based upon IDH and 1p/19q status, as well as the potential roles of methylation profiling and deletional analysis of cyclin-dependent kinase inhibitor 2A and 2B. We discuss the epidemiology, clinical manifestations, benefit of surgical resection, and neuroimaging features of lower-grade gliomas as they relate to molecular subtype, including advanced imaging techniques such as 2-hydroxyglutarate magnetic resonance spectroscopy and amino acid PET scanning. Recent, ongoing, and planned studies of radiation therapy and both cytotoxic and targeted chemotherapies are summarized, including both small molecule and immunotherapy approaches specifically targeting the mutant IDH protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.